A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2011
12/22/2011	US20110312876 Method of determining types I, II, III, IV or V or methicillin-resistant staphylococcus aureus (MRSA) in a biological sample
12/22/2011	US20110312875 Peptidic compounds
12/22/2011	US20110312874 Use of a trpc channel for the treatment of a cardiovascular disease
12/22/2011	US20110312873 N-terminally modified tetrapeptide derivatives having a c-terminal arginine mimetic
12/22/2011	US20110312872 Norrin in the treatment of diseases associated with an increased tgf-beta activity
12/22/2011	US20110312519 Genetic factors associated with inhibitor development in hemophilia a
12/22/2011	US20110312086 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
12/22/2011	US20110311651 Cardenolides for the treatment of ocular cancer
12/22/2011	US20110311650 Multiplexed biomarkers of insulin resistance
12/22/2011	US20110311647 Biofilm-removing antimicrobial compositions and uses thereof
12/22/2011	US20110311643 Supplemented matrices for the repair of bone fractures
12/22/2011	US20110311640 Cosmetic compositions comprising asteroidea body fluid and methods of use thereof
12/22/2011	US20110311621 Pharmaceutical compositions and methods of delvery
12/22/2011	US20110311613 Topical formulations of flap inhibitors for the treatment of dermatological conditions
12/22/2011	US20110311609 Wound healing device
12/22/2011	US20110311594 Controlled release compositions with reduced food effect
12/22/2011	US20110311591 Antimicrobial Coating
12/22/2011	US20110311585 Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
12/22/2011	US20110311566 Methods and materials for generating t cells
12/22/2011	US20110311564 Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles
12/22/2011	US20110311561 Non-natural mic proteins
12/22/2011	US20110311555 Tc11 as a Transcriptional Regulator
12/22/2011	US20110311554 Compositions and Methods for Suppressing Fibrocytes
12/22/2011	US20110311548 Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system
12/22/2011	US20110311541 Mutant proteins of the f protein of piv-5 and piv-2
12/22/2011	US20110311540 Wisp polypeptides and nucleic acids encoding same
12/22/2011	US20110311537 Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
12/22/2011	US20110311533 Regulation of protein level
12/22/2011	US20110311531 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/22/2011	US20110311530 Truncated baff receptors
12/22/2011	US20110311529 Method for treating a rheumatic disease using a soluble tla4 molecule
12/22/2011	US20110311528 Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of psoriasis
12/22/2011	US20110311525 Delivery of a cd40 agonist to a tumor draining lymph node of a subject
12/22/2011	US20110311521 Novel therapy for anxiety
12/22/2011	US20110311518 Novel synthetic agonists of tlr9
12/22/2011	US20110311512 Genetic Variants Underlying Human Cognition and Methods of Use Thereof as Diagnostic and Therapeutic Targets
12/22/2011	US20110311511 CRYSTAL STRUCTURE OF PfA-M1 AND THE PfA-M1 Co4 COMPLEX
12/22/2011	US20110311509 Treatment of ocular diseases
12/22/2011	US20110311508 Method of modulating hsf-1
12/22/2011	US20110311507 Methods for Diagnosing and Treating Autoimmune Disorders
12/22/2011	US20110311506 Piggybac transposon variants and methods of use
12/22/2011	US20110311505 Photosensitive Aminoacid-Monomer Linkage and Bioconjugation Applications in Life Sciences and Biotechnology
12/22/2011	US20110311499 Secretion System and Methods for its Use
12/22/2011	US20110311492 MAINTENANCE/EXPANSION OF HSC's
12/22/2011	US20110311485 1,2,4-oxadiazole derivatives and their therapeutic use
12/22/2011	US20110311484 Strains of xenotropic murine leukemia-related virus and methods for detection thereof
12/22/2011	US20110311483 Crth2 modulators
12/22/2011	US20110311482 Hepatitis C Virus Inhibitors
12/22/2011	US20110311481 Methods and Compositions for Contributing to the Treatment of Cancers
12/22/2011	US20110311480 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
12/22/2011	US20110311479 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
12/22/2011	US20110311478 Combinatorial Methods For Treating Cellular Proliferative Disorders And Immune Deficiencies Using Salicinium
12/22/2011	US20110311477 Infusion Treatment Methods And Compositions Using Salicinium For Treating Cellular Proliferative Disorders And Immune Deficiencies
12/22/2011	US20110311476 Methods For Treating An Immune Deficiency Or Enhancing Immune Function Using Salicinium, Non-Limited In Terms Of Treatment Indication, But Encompassing Methods For Treating Cancer And Microbial, Bacterial, Viral, Fungal; Non-Limited In Terms of Delivery Mode, Formulation
12/22/2011	US20110311475 Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
12/22/2011	US20110311474 Novel Tricyclic Compounds
12/22/2011	US20110311473 Methods of treating cognitive impairment
12/22/2011	US20110311472 Application of mrna for use as a therapeutic against tumour diseases
12/22/2011	US20110311462 Compositions for treatment of ear disorders and methods of use thereof
12/22/2011	US20110311454 Molecules with extended half-lives, compositions and uses thereof
12/22/2011	US20110311446 Peptides that specifically bind hgf receptor (cmet) and uses thereof
12/22/2011	US20110311445 Diagnosis and treatment of myeloid and lymphoid cell cancers
12/22/2011	US20110311443 Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
12/22/2011	US20110311442 Direct cellular energy delivery system
12/22/2011	DE10344561B4 Verwendung eines Tetra-, Penta- und Octapeptids aus Gelée Royale Use of tetra-, penta- and octapeptide of royal jelly
12/22/2011	DE102010024359A1 Drugs- or dietary supplements useful for the treatment and/or prophylaxis of joint disease, comprise a collagen hydrolyzate and free hydroxyproline
12/22/2011	CA2805412A1 Therapeutic and cosmetic uses and applications of calreticulin
12/22/2011	CA2805406A1 Growth hormone secretatogue receptor antagonists and uses thereof
12/22/2011	CA2803317A1 Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
12/22/2011	CA2802999A1 Method for predicting a therapy response in subjects with multiple sclerosis
12/22/2011	CA2802994A1 Compositions and methods for treating inflammatory conditions
12/22/2011	CA2802912A1 Innate defence regulatory peptide compositions for treatment of arthritis
12/22/2011	CA2802726A1 Long lasting drug formulations
12/22/2011	CA2802665A1 Peptide having antibacterial or anti-inflammatory activity and pharmaceutical composition containing the same as an active ingredient
12/22/2011	CA2802477A1 Agent for treating hcv infection
12/22/2011	CA2802471A1 Novel peptides for wound healing
12/22/2011	CA2802388A1 Compositions and methods for treating cancer
12/22/2011	CA2802072A1 Treatment of coagulopathy with hyperfibrinolysis
12/22/2011	CA2800757A1 Stabilised human immunoglobulin composition
12/21/2011	EP2397555A1 Fusion proteins of mycobacterium tuberculosis antigens and their uses
12/21/2011	EP2397549A2 Non-stochastic generation of genetic vaccines and enzymes
12/21/2011	EP2397494A1 Human antibodies that bind human TNFalpha
12/21/2011	EP2397493A1 Compositions and methods for modulating immune responses
12/21/2011	EP2397489A1 Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti-HIV-I prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention
12/21/2011	EP2397488A1 Dipeptide mimetics of ngf and bdnf neurotrophins
12/21/2011	EP2397152A2 Use of cardiotrophin- 1 for the treatment of metabolic diseases
12/21/2011	EP2397151A1 Treatment of vascular complications of diabetes
12/21/2011	EP2397150A1 Biopolymer, implant comprising it and uses thereof
12/21/2011	EP2397149A1 Pharmaceutical preparation comprising actinomycin D for the treatment of B-CLL in patients having del(17p)
12/21/2011	EP2397148A2 Compositions and methods for the treatment of ophthalmic disease
12/21/2011	EP2396348A1 Methods for inducing transplantation tolerance
12/21/2011	EP2396345A1 Antimicrobial peptides based on cmap27
12/21/2011	EP2396038A2 Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
12/21/2011	EP2396029A1 Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
12/21/2011	EP2396028A2 Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
12/21/2011	EP2396027A2 Combined treatment of multiple sclerosis
12/21/2011	EP2396026A2 Compositions and methods for minimally-invasive systemic delivery of proteins including tgf- superfamily members
12/21/2011	EP2396025A2 Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease
12/21/2011	EP2396024A1 Use of antisecretory factors (af) for optimizing cellular uptake
12/21/2011	EP2396023A2 Short beta-defensin-derived peptides

1 ... 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 ... 3163